6. October 2009 07:15
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the FDA Oncologic Drug Advisory Committee voted in favor of recommending approval of PEGINTRON® as a treatment in addition to surgery in patients with metastatic melanoma. The product is currently being marketed, manufactured and developed by Schering-Plough. PEGINTRON (Peginterferon alfa-2b) is currently indicated for treatment of chronic hepatitis C in patients 18 years of age or older with compensated liver disease and previously untreated with interferon alpha. PEGINTRON is also indicated for use in combination with REBETOL® (ribavirin) for the treatment of chronic hepatitis C in patients 3 years of age and older with compensated liver disease. PEGINTRON is one of several products which utilize Enzon’s PEGylation technology, including CIMZIA®, Macugen®, and Pegasys®.
“We congratulate Schering-Plough for this great achievement. PEGINTRON provides effective treatment to hepatitis C patients and we are pleased Schering-Plough continues to explore its use in additional areas,” said Jeffrey H. Buchalter, Enzon's president and chief executive officer.
http://www.enzon.com/
News-Medical.Net provides this medical information service in accordance
with these
terms and conditions.
Please note that medical information found
on this website is designed to support, not to replace the relationship
between patient and physician/doctor and the medical advice they may provide.
Subscribe